An Official Website of the United States Government
Company Information:
Name:
IMMURX LLC
Address:
16 Cavendish Court
LEBANON, NH 03766-
LEBANON, NH 03766-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Potent Vaccine Adjuvant Therapeutic
Award Year / Program / Phase:
2009 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Hillary D. White
Award Amount:
$577,222.00
Abstract:
DESCRIPTION (provided by applicant): Protective immunity against chronic infectious diseases such as TB will almost certainly require the generation of potent cellular immunity. To that end, we have recently developed a proprietary form of immunization (co
mbined TLR/CD40-agonist immunization) which… More
Creation of an Anti-CD40 Superagonistic Monoclonal Antibody
Award Year / Program / Phase:
2009 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Hillary D. White
Award Amount:
$329,936.00
Abstract:
Description: The overall goal of this revised SBIR application is to produce and test monoclonal antibodies (mab) to human CD40 that possess super-agonistic activity, as part of an adjuvant platform. The term superagonist is defined by specific immuno
logical activities that these mabs possess,… More
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Susan D. Jones
Award Amount:
$537,514.00
Abstract:
DESCRIPTION (provided by applicant): The early infiltration by leukocytes into the tumor microenvironment leads to neovascularization, enhanced tumor growth, metastasis and lethality of the host. Notably, leukocytes enable tumor establishment, as suggeste
d early on by Virchow in 1826 and proven… More
VISTA: A Novel Therapeutic Target That Negatively Regulates Immunity
Award Year / Program / Phase:
2011 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Susan D. Jones – 603-321-6623
Award Amount:
$600,000.00
Abstract:
DESCRIPTION (provided by applicant): We have discovered, characterized and functionally defined a novel, immune inhibitory ligand. This ligand is hematopoietically-expressed, a distant member of the B7 Ig-superfamily, and its extracellular domain bears homology to the B7 family ligand PD-L1. This… More
Preclinical Development of a Novel and Powerful Immunotherapeutic
Award Year / Program / Phase:
2011 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Susan D. Jones – 603-321-6623
Award Amount:
$2,776,441.00
Abstract:
DESCRIPTION (provided by applicant): ImmuRx is developing a novel and potent immunotherapeutic product to stimulate the immune system. This will significantly increase the efficacy of existing and new therapeutic vaccines for the treatment of cancers suchas melanoma, lymphoma and lung cancer and… More
Safe and effective anti CD154 antibodies for therapeutic intervention
Award Year / Program / Phase:
2012 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Susan D. Jones – 603-321-6623
Award Amount:
$300,000.00
Abstract:
DESCRIPTION (provided by applicant): In both animal proof of concept studies and preliminary clinical trials, there is ample data demonstrating the potential therapeutic benefits o CD154 blockade for treatment of autoimmune diseases and organ transplantation. However, development of ?CD154 as a… More